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SUMMARY
Microstructural equivalence (Q3) for dry powder inhalers (DPIs) is complex because it involves 
both pre- and post-aerosolization powders and can be influenced by the DPI device and the 
patient’s aerosolization efficiency. In this paper, we show how advanced 3D X-ray microscopy 
(XRM, also known as X-ray computed tomography) techniques can provide unique microstructural 
insights into pre-aerosolized inhalation powders. Nano-scale XRM is used to detect differences 
within individual lactose particles and agglomerates, including voids and intra-agglomerate size 
distributions. Micro-scale XRM is used to visualize and quantify lactose fines (<12 mm) within a 
powder bed. XRM is also used to discriminate between excipient and terbutaline sulphate particles 
in an inhalation blend. These advanced XRM techniques could provide valuable microstructural 
information to help address Q3 equivalence during bioequivalence determination in inhalation 
drug products.
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INTRODUCTION
Demonstrating pharmaceutical equivalence and bioequivalence (BE) between a test and reference 
product are important requirements in the development of generic inhalation products [1]. BE is 
also essential to support post-approval formulation or manufacturing process changes for existing 
orally inhaled drug products [1]. BE is defined as the absence of a significant difference in the 
rate and extent to which the active ingredient reaches the site of drug action when administered 
at the same dose and under similar conditions [2]. For systemically acting drugs, BE is typically 
demonstrated using pharmacokinetic (PK) studies, comparing drug plasma concentrations between 
the test and reference products. However, the ability of PK studies to assess BE for locally acting 
inhaled drugs remains controversial because their delivery and intended action in the lung does 
not rely on the systemic circulation [2–6]. Instead, the US Food and Drug Administration (FDA) 
utilizes a weight-of-evidence approach which includes in vitro, PK and pharmacodynamic (PD) or 
clinical studies to demonstrate BE of inhalation products [2].  Alternative pathways to establish BE 
in these complex drug-device combination products are currently being explored. 
The FDA introduced the concept of microstructural equivalence (Q3) where differences 
between the same components (Q1) in the same concentration (Q2) under a non-equilibrium state 
can be related to the arrangement of matter and/or its state of aggregation. For topical and transdermal 
creams, gels and suspensions, if Q1 and Q2 are identical, then the difference is considered to be 
due to Q3 [7]. However, inhaled therapies are more challenging because microstructural changes 
of the inhaled formulation are not only due to manufacturing and formulation processes, but also 
as a result of the aerosolization process. Thus, there is a need to investigate the microstructural 
relationship between both formulated and aerosolized forms of the product, in order to address Q3 
equivalence in inhaled drug formulations.  
ASSESSING Q3 STRUCTURAL EQUIVALENCE 
IN INHALED PRODUCTS
Recently Price et al. reported differences in the in vitro dissolution profiles of Advair® Diskus® 
and Seretide® Accuhaler® dry powder inhalers (DPIs) (GlaxoSmithKline, USA and UK) and 
highlighted differences in the state of aggregation of the active pharmaceutical ingredients 
(APIs) and excipients using morphology-direct Raman spectroscopy (MDRS) [8, 9]. Whilst this 
orthogonal approach using in vitro dissolution testing coupled with MDRS characterization can 
detect subtle differences in the post-aerosolized product, the role of any microstructural differences 
in the pre-aerosolized material that may contribute to this behavior remains unknown. Linking 
the microstructure of the pre-aerosolized formulation with the performance of the inhaled product 
is needed and some critical questions still remain unanswered: What does the microstructure of 
the formulation really look like? How does processing change this microstructure? And how do 
microstructural differences in the formulation manifest in the final aerosolization performance? 
With these questions in mind, the INFORM 2020 consortium was formed with funding from 
the United Kingdom’s Engineering and Physical Sciences Research Council, bringing together 
academic institutions, pharmaceutical companies and technology experts to develop new techniques 
to characterize the Q3 microstructure. 
The potential of X-ray Computed Tomography (XCT) to provide unique three-
dimensional microstructural insight of pharmaceutical formulations has long been of interest [10, 11]. 
However, the small particle sizes associated with inhalation blends have been a major obstacle to 
the widespread use of the technology. Improvements in instrument technology, in particular the 
development of x-ray optical elements [12], over the past 10 years has allowed higher resolution 
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and improved contrast to be achieved on laboratory systems. Such is the level of detail provided 
by the x-ray optics that these XCT machines are alternatively known as x-ray microscopes, giving 
rise to the field of x-ray microscopy (XRM) [13, 14]. Recently, x-ray microscopes have been used as 
multiscale characterization tools for inhalation powders, providing information on meso-, micro- 
and nano-scales [15]. XRM has also been shown to quantify particle size and shape in 3D, and 
provide information on the number and positions of fine lactose particles in the powder bed [16]. 
In this paper, we show how these new XRM techniques can help unlock further microstructural 
features of inhalation blends.  
VISUALIZING INTERNAL STRUCTURES USING
PHASE-CONTRAST X-RAY MICROSCOPY (XRM)
As x-rays pass through a sample, two ways that they are affected are attenuation and diffraction [17]. 
First, the x-rays are attenuated, with the absorption proportional to atomic number (Z). Denser 
elements attenuate x-rays to a greater degree, and hence materials with different densities can be 
distinguished through different grayscale values within a reconstructed slice of a 3D dataset. For 
example, the different grayscale values within the Diskus/Accuhaler DPI shown in Figure 1 show 
different density materials. Second, x-rays are diffracted, i.e. the phase of the x-ray wave is shifted. 
The interaction between a diffraction wave and an un-diffracted wave produces characteristic white 
and dark fringes that are known as Fresnel fringes at the edges and boundaries in the sample where 
there is a change in the index of refraction [18]. Absorption scans are typically quicker than pure 
phase contrast scans and provide sufficient contrast in many cases. However, for low Z materials 
such as organic compounds including pharmaceuticals, where the differences in x-ray absorption 
of different phases are minimal, there is insufficient contrast to differentiate different compounds 
[19, 20]. The phase contrast modality is typically slower than absorption mode as the signal on 
the detector is weaker and additionally requires the use of dedicated Zernike phase rings [21] or a 
combination of highly coherent sources and large propagation distances at which the phase fringes 
are better resolved [18]. In the case of low Z materials, the dominant contrast mechanism is through 
phase shift occurring at particle boundaries or interfaces where there is a significant difference in 
the index of refraction, providing high contrast sensitivity to otherwise weakly absorbing features 
such as voids, porosity and boundaries between very similar materials [22]. 
 
Figure 1.   An example of absorption-contrast can be seen in an XRM scan of an Accuhaler (GlaxoSmithKline, 
United Kingdom), with a cross-sectional virtual slice (left) and 3D rendering (right). The different 
grayscale values in the left panel correspond to different density materials within the inhaler. 
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Figure 2 shows the same vertical cross-sectional slice from 3D reconstructions of a Lactohale 206 
sample scanned using both absorption and phase-contrast modalities on a Zeiss Xradia 810 Ultra 
system (Carl Zeiss Microscopy, USA). The sample was prepared by mounting particles from a batch 
of Lactohale 206 powder (DFE Pharma, Germany) on the end of a dress-maker pin using epoxy 
resin. The Ultra 810 is a nano-scale XRM instrument using a monochromatic parallel x-ray beam 
of 5.4 keV photons, with the capability of both absorption contrast and phase-contrast modalities 
through a Zernike phase-ring. The Ultra system allows samples up to 64 mm to be scanned at a 
spatial resolution of 150 nm whilst samples smaller than 16 mm can be scanned at a 50 nm spatial 
resolution. The detector binning was set at 2×, with each projection image 512 × 512 pixels in size. 
801 projections were collected as the sample was rotated through 360o for both scans, with Nyquist 
sampling theorem suggesting the number of projections should be p/2 multiplied by the projection 
image width [23]. The exposure time for each projection was 10 s and 30 s for the absorption-
contrast and phase-contrast scans respectively. The phase-contrast modality of XRM (Figure 2B) 
provides greater contrast than the absorption modality (Figure 2A) allowing the identification of 
two separate particles separated by the epoxy. The entirety of Particle 1 is contained within the 
field of view, but only a part of Particle 2 can be seen. The epoxy on two sides of Particle 2 would 
suggest that this particle has been immersed entirely in the resin. A 3D visualization of the entire 
sample can be seen in Figure 2C, where two smaller particles can be seen attached to Particle 2. The 
phase-contrast also allows further details of the microstructure to be uncovered. Multiple line-voids 
were observed within the particles that appear to align in the same direction within each individual 
crystal. The cause of the particle voids is currently under investigation, which may be induced by 
sample preparation or a function of lactose manufacture. However, since the voids in Particle 1 
are aligned diagonally upwards, whilst those in Particle 2 are vertical, this indicates the ability of 
XRM to identify intra-particulate features with their directionality based on particle orientation. 
Furthermore, no voids were seen within a control recrystallized lactose particle that was mounted 
using the same epoxy resin method (Figure 2D), indicating the potential ability of XRM to detect 
the impact of manufacturing process differences on particle properties. Further work is needed to 
test a range of different samples and lactose grades, but XRM coupled with nano-indentation could 
help our understanding on how these voids influence particle fracture [24]. 
As seen above, the Fresnel phase-contrast fringes [18] provide a sharp boundary that helps 
identify parts of a sample. Phase-contrast fringes were also beneficial in [16] for separating lactose 
particles within a bulk powder. However, in many cases phase-contrast can make segmentation 
(i.e. partitioning the digital image into multiple segments to identify different phases or particles) 
more challenging. It is worth noting that while the edges are sharply defined, the overall grayscale 
contrast between the air and particles is reduced in the phase contrast images (Figure 2B) compared 
to the absorption images (Figure 2A).
ASSESSING THE STRUCTURE OF MICRONIZED-PARTICLE
AGGLOMERATES USING XRM
The structure and behavior of microparticles (both API and excipient ‘fines’) have been shown to 
play a key part in the control of aerosolization performance [25]. However, micronized particles 
tend to be highly cohesive and naturally form agglomerates or granular ‘pseudo’-particles [26]. 
Knowledge of the agglomerate microstructure is important for understanding de-agglomeration, 
but these pseudo-particles present a major challenge for microstructural analytical techniques 
such as optical microscopy, scanning-electron microscopy or laser diffraction which are unable 
to determine the intra-agglomerate structure. The non-destructive capability of nano-scale XRM 
with phase-contrast modality to investigate interior particulate structures was utilized to examine a
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Figure 2.  Virtual vertical cross-sectional slices through reconstructions of a Lactohale 206 sample scanned 
with nano-XRM using (A) absorption contrast and (B) phase-contrast. (C) 3D visualization of 
the same Lactohale 206 sample, with the epoxy rendered transparent and the cracks shown in 
green. (D) Virtual vertical cross-sectional slice through a reconstruction of a control recrystallized 
lactose sample. 
Lactohale 300 (LH300) agglomerate. The agglomerate was mounted on the end of a dress maker pin 
using epoxy resin and scanned using the Zeiss Xradia Ultra 810 XRM instrument using the same 
phase-contrast scan settings described previously. but with an exposure time of 60 s per projection. 
The final 3D virtual volume was reconstructed using the proprietary Zeiss Reconstructor software. 
 A single cross-sectional slice through the virtual volume is shown in Figure 3A. Although 
the different particles within the agglomerate can be clearly seen, there is little grayscale difference 
between the particles and surrounding air (i.e. void space within the agglomerate) making 
segmentation of the lactose phase very challenging. However, post-processing the virtual volume 
with a proprietary phase retrieval algorithm (Carl Zeiss Microscopy, USA) minimizes the phase 
fringes seen along the edges and enhances the grayscale contrast as shown in Figure 3B [27]. The 
implementation is based on modelling the physical diffraction with an image filter model, with the 
phase retrieval and correction performed by de-convolving the appropriate filter function with the 
acquired data [28]. From the simpler dataset, the lactose phase can be easily segmented. Furthermore, 
individual particles within the agglomerate can be identified and thus a size-distribution of the 
individual, constituent micro-particles that form the agglomerate deduced as shown in Figure 3C. 
The distribution is bimodal, with the first mode about 0.5 mm and a second mode about 2.5 mm. 
The cross-sectional slice (Figure 3A) appears to show some organization between the particles, and 
Figure 3D shows a 3D visualization of the agglomerate with each of the particles colored by the 
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particle size. Further work is needed to quantify the relative spatial positions of the different sized 
particles within the agglomerate which could provide valuable insight into the cohesive nature of 
micronized powders.  
Figure 3.  (A) A single raw horizontal virtual cross-sectional slice through an LH300 agglomerate. (B) The 
same slice after processing using a phase-retrieval filter. Notice the distinct grayscale values between 
air (void space) and lactose particles. (C) Size distribution for all of the particles identified within 
the agglomerate. (D) 3D visualization of the LH300 agglomerate with each particle colored by its 
size, with the range given by the color bar in the bottom left corner of (D) and at the top of (C). 
SPATIAL DISTRIBUTION OF FINES IN INHALATION BLENDS
The addition of fine lactose particles increases the cohesiveness of a bulk lactose powder and 
thus reduces the powder flowability [25, 29]. Kopsch, Murnane and Symons [30] visualized the 
entrainment of three different lactose powders (Respitose SV003 (fine, sieved lactose), Lactohale 
100 (sieved lactose) and Lactohale 200 (milled lactose); all DFE Pharma, Germany) using a 
high speed camera at 1000 frames per second. The entrainment behavior of Respitose SV003 
and Lactohale 100 was found to be consistent, reproducible and corresponded well with CFD 
results. However, the fluidization behavior of Lactohale 200 was found to be chaotic, with different 
entrainment behavior for each run even though the experimental setup was identical. The authors 
acknowledged that non-reproducible entrainment behavior of Lactohale 200 could be related to 
the increased cohesivity of the milled lactose grade from a higher proportion of fines compared to 
the sieved grades Respitose SV003 and Lactohale 100 [30]. 
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Figure 4.  3D Visualizations of (A) Lactohale 100 and (B) Lactohale 200, with particles smaller than 12 mm 
colored orange, and those larger than 12 mm in gray. 
The spatial positions of fine particles in Lactohale 100 and Lactohale 200 for dry powder inhaler 
formulations have recently been reported [16]. Figure 4 shows 3D visualizations of the data from 
[16], with particles less than 12 mm in size colored orange and those larger than 12 mm in gray. 
Furthermore, it was possible to quantify the number of sub-12 mm fines by identifying eight non-
overlapping regions of interest (ROI) within the full analysis volume and counting the number of 
fines in ROI. Dividing by the volume of the ROI gave the number density, with Lactohale 100 
containing 9426 ± 559 particles per mm3 and Lactohale 200 containing 66458 ± 6033 particles per 
mm3. Whilst Lactohale 200 has more than seven times as many fines compared to Lactohale 100, 
the high spatial variation in the number of fines could offer an explanation for the inconsistent 
entrainment behavior. Further work is underway to quantify the number of fines across a range of 
powders and link this to other physical properties. 
REVEALING MULTIPLE SPECIES IN INHALATION BLENDS
The key component of an inhalation blend is the API, and effective de-agglomeration of the drug 
from the carrier particles is critical to the performance. De-agglomeration is linked to the spatial 
interactions of drug and excipient and XRM could be a useful exploratory tool due its intrinsic 
three-dimensional nature. A blend of Capsulac 60 (Meggle, Germany) and terbutaline sulphate 
(TBS) in a 9:1 mass ratio was mixed using a Turbula mixer (Willy A Bachofen, Basel, Switzerland) 
at a frequency of 30 Hz for 1 h. Capsulac 60, a tableting grade lactose, was chosen as a model carrier 
in the blend due to its larger size. The TBS-Capsulac 60 blend was loaded by hand into a Kapton 
tube sample holder [15] and scanned using a Zeiss Xradia Versa 520 micro-XRM instrument (Carl 
Zeiss Microscopy, USA). A 10× objective lens was used, with 2× detector binning and source-to-
sample and sample-to-detector distances of 12 mm and 14 mm respectively, giving a reconstructed 
voxel size of 1.27 mm3. As the size of each projection was 1005 × 1005 pixels, 1601 projections were 
collected as suggested by the Nyquist sampling theorem. Each projection had a 12.5 s exposure time. 
A voltage of 40 kV and current of 75 mA was used to maximize any absorption contrast between 
(A) (B)
108 Unlocking the Microstructure of Inhalation Blends using X-Ray Microscopy – Gajjar et al.
the different density Capsulac 60 and TBS. The Versa system produces in-line phase contrast due 
to the highly coherent source, and thus the final volume contains some absorption contrast along 
with Fresnel fringes.
 
Figure 5.  (A) Virtual horizontal cross-sectional slice through the blend of terbutaline sulphate and 
Capsulac 60. (B) A zoomed section of the same slice with several particles highlighted that have 
uncharacteristically bright grayscale color.
Figure 5A shows a single cross-sectional slice through the virtual volume. Although the Fresnel 
fringes can be seen at the edges of particles that reveal the particle boundaries in detail, they 
alone are not sufficient in the identification of the two species. In fact, in some cases they may 
pose additional difficulties in the phase identification. X-ray absorption is proportional to material 
density and since the densities follow air (0.001 kg/L) < TBS (1.18 kg/L) < lactose (1.54 kg/L), the 
grayscale values should also follow with air being the darkest and lactose the lightest. However, 
Figure 5B shows a zoomed section of the cross-sectional slice with several example small particles 
circled, where the grayscale value is brighter than the surrounding lactose. This is due to the bright 
ring from the Fresnel fringe making the grayscale value across the entire small particle very bright. 
Thus, from the raw reconstructed volume alone, it is extremely challenging to distinguish between 
the lactose and TBS that are both low Z materials with only small density differences.
After post-processing the raw reconstructed data with the phase-retrieval algorithm 
(to minimize phase fringes seen at particle boundaries and enhance grayscale contrast), there 
are distinct grayscale values for the two species allowing particles of each to be identified. Figure 
6A shows a 3D visualization with Capsulac 60 colored gray and TBS colored green, with the 
proportion of TBS calculated to be 8.1%. Although this is lower than the expected proportion 
of 10% TBS in the blend, this may be due to segregation and/or errors in identifying the two 
species. It is possible to verify the segmentation by obtaining size-distributions of the two phases, 
as shown in Figure 6B. The size distribution of the TBS phase is less than 75 mm, whilst that 
of Capsulac 60 is between 100 and 400 mm. The size distribution of Capsulac 60 identified in 
the blend is slightly different from that of pure Capsulac 60 analyzed in [16] and plotted here 
for comparison. Although the size range is broadly similar, the distribution determined from the 
(A) (B)
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blend has a bimodal distribution. This could be due to powder aggregates breaking up during the 
blending process. Examining the morphology of the two phases, the Capsulac 60 particles have 
the characteristic lactose tomahawk shape [31], sometimes with particles aggregated together as 
shown in Figure 6C. By contrast, the identified TBS particles have a plate-like morphology [32] 
as shown in Figure 6D. Further work is currently underway to improve the particle separation 
and extend the technique to blends containing inhalation grade lactose. Although the results are 
promising, it will be necessary to validate the identification of different chemical species using the 
phase retrieval algorithm by comparison to existing techniques such as Energy-dispersive X-ray 
spectroscopy (EDX). Note that EDX requires dispersion of the powder sample whilst XRM is the 
only technique able to look inside a bulk powder. 
 
Figure 6. (A) 3D visualization of Capsulac 60 – TBS blend, with Capsulac 60 colored gray and TBS colored 
green. (B) Size distribution of the two identified phases, with pure Capsulac 60 plotted alongside 
for comparison. Pure Capsulac 60 data reproduced from Gajjar et al. [16] under a Creative 
Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/). 
(C) Typical Capsulac 60 morphology, showing the characteristic tomahawk shape arranged in an 
aggregate. (D) Typical plate-like TBS morphology. 
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CONCLUSIONS
X-ray microscopy with phase-contrast modality has the potential to provide unique insight into the 
microstructure of pre-aerosolized DPI formulations. Nano-scale XRM allows internal features, e.g. 
voids, of individual particles to be revealed. This level of detail is unrivalled and could allow direct 
comparisons between batch-to-batch and site-to-site manufacturing variability. Furthermore, nano-
scale XRM allows quantification of microstructural features within agglomerates such as the internal 
particle size distribution. If other information such as porosity and contact areas can also be extracted, 
then nano-scale XRM could provide a valuable link between the pre- and post-aerosolized product. 
Micro-scale XRM allows individual drug and excipient particles to be identified within a powder 
sample. Unique to XRM is that it is non-destructive, potentially opening doors as a process analytical 
technology (PAT) [33] for production line assessment of formulations within capsules and blisters. 
Further work is certainly needed, but promising early signs are that XRM could potentially unlock the 
assessment of microstructure of inhaled formulations and provide a bridge between Q3 and BE studies. 
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